Introduction {#s01}
============

Actin--myosin cross-bridge interactions use energy from ATP hydrolysis to generate the contractile force in cardiac muscle, which enables the heart to pump blood throughout the body. Troponin, a regulatory protein on the thin filament, binds intracellular Ca^2+^ and interacts with tropomyosin to biochemically regulate these cross-bridge interactions. Structural changes that accompany variations in sarcomere length (SL) also modulate the degree of thick and thin filament overlap to influence the number of cross-bridges available to generate force throughout a heartbeat ([@bib60]; [@bib9]). Myosin regulatory light chain (RLC) binds to the neck of myosin, and posttranslational phosphorylation of RLC is thought to augment force production by increasing cross-bridge recruitment to the force-generating population ([@bib37]; [@bib53], [@bib54]; [@bib55]; [@bib39]; [@bib52]; [@bib8]).

Recent observations from our laboratory suggest that cross-bridge cycling kinetics slow with increases in SL related to a reduced rate of magnesium adenosine diphosphate dissociation from cross-bridges ([@bib59]). We also found that RLC phosphorylation decreases the magnesium adenosine triphosphate binding rate, making cross-bridge detachment occur more slowly ([@bib45]). This finding was consistent with previous studies suggesting that RLC phosphorylation slows cross-bridge detachment ([@bib15]; [@bib43]; [@bib39]; [@bib52]; [@bib19]; [@bib8]), although other groups have proposed that RLC phosphorylation repositions myosin heads nearer to thin filaments, to facilitate cross-bridge recruitment ([@bib54]; [@bib29]; [@bib52]; [@bib8]).

Contractility of the cardiac atria and ventricles is modulated by various percentages of α- and β-cardiac myosin heavy chain, depending on the species and health of the heart ([@bib31]; [@bib46]; [@bib47]). Previously, our laboratory used skinned myocardial strips from the left ventricle of rats to assess the individual and combined effects of RLC phosphorylation and SL on myosin kinetics, the isometric force--free calcium concentration (pCa = −log\[Ca^2+^\]) relationship, and viscoelastic myocardial stiffness ([@bib59]; [@bib45]). These myocardial strips predominantly expressed the faster cardiac myosin heavy chain isoform (α-cardiac; *Myh6* gene). Thus, we sought to assess how RLC phosphorylation influences length-dependent myosin function and cardiac contractility as myosin motor speed varies, by using myocardial strips expressing the slower cardiac myosin heavy chain isoform (β-cardiac; *Myh7* gene). We hypothesized that the effects of RLC phosphorylation on cross-bridge function would be amplified at longer SLs because of slower cross-bridge cycling rates in myocardial strips expressing primarily β-myosin heavy chain. To test this hypothesis, we fed rats 6-*n*-propyl-2-thiouracil (PTU) to induce \>95% expression of the slower β-myosin heavy chain isoform in the cardiac ventricles. We then measured tension--pCa relationships and myosin cross-bridge kinetics, as RLC phosphorylation varied at short and long SLs in skinned papillary muscle strips from these rats. We found that RLC phosphorylation increased both Ca^2+^ sensitivity of the tension--pCa relationship and maximal tension development of the tension--pCa relationship at 2.2-µm SL, but not at 1.9-µm SL. Thus, RLC phosphorylation may enhance cardiac contractility only at longer SLs in myocardial tissue expressing predominantly the β-myosin heavy chain isoform. We also found that the β-myosin heavy chain cross-bridge detachment rate slows under maximally activated conditions (pCa 4.8) at the longer 2.2-µm SL. We observed a more significant length-dependent effect in this current study in myocardial strips predominantly composed of β-myosin heavy chain, versus the length-dependent effects seen in our previous study of strips primarily composed of α-myosin heavy chain. These findings may represent molecular mechanisms to accommodate increased contractile demand at longer SL caused by increased diastolic filling in regions of the heart expressing predominantly β-myosin heavy chain, such as the human cardiac ventricles ([@bib22]).

Materials and methods {#s02}
=====================

Animal models {#s03}
-------------

All procedures were approved by the Institutional Animal Care and Use Committee at Washington State University and complied with the *Guide for the Use and Care of Laboratory Animals* published by the National Institutes of Health. Adult male Sprague-Dawley rats were acquired from Simonsen Laboratories and fed an iodine-deficient 0.15% PTU chow (Harlan Teklad) for 10 wk, at which point they were euthanized (*n* = 8, age 16--20 wk). This diet shifts the myosin isoform expression profile from predominantly α-myosin heavy chain to β-myosin heavy chain in rodents ([@bib44]; [@bib13]; [@bib41]; [@bib14]; [@bib63]). Expression of many myofilament regulatory proteins has been shown to be unaffected by hypothyroidism, including troponin T, I, and C; myosin light chain I (essential light chain) and II (RLC); actin; and α-tropomyosin ([@bib13]; [@bib14]). Rats were anesthetized by isoflurane inhalation (3% volume in 95% O~2~-5% CO~2~ flowing at 2 liters/min), and hearts were immediately excised and placed in dissecting solution on ice.

Biochemical quantification of myosin isoform content {#s04}
----------------------------------------------------

Myosin isoform expression was measured via gel electrophoresis, as previously described ([@bib46]). Left ventricle samples were taken from (a) sex- and age-matched control rat hearts that were fed a standard laboratory diet (5001; LabDiet) and (b) each PTU-treated rat heart. The samples were run in duplicate, and gels were stained with Coomassie Brilliant blue (Thermo Fisher Scientific) and scanned on a Perfection v750 Pro (Epson). The relative optical densities of α-myosin heavy chain to β-myosin heavy chain isoform were quantified with ImageJ (National Institutes of Health). Among all PTU-treated rat cardiac samples, β-myosin heavy chain content was \>95% ([Fig. 1](#fig1){ref-type="fig"}).

![**Effect of PTU on cardiac myosin heavy chain expression.** Gel electrophoresis of left ventricle tissue homogenate stained with Coomassie blue shows the predominant shift toward β-myosin heavy chain expression in PTU-fed rats. MHC, myosin heavy chain.](JGP_201812158_Fig1){#fig1}

Solutions for skinned myocardial strips {#s05}
---------------------------------------

Muscle mechanics solution concentrations were formulated by solving equations describing ionic equilibria according to [@bib17], and all concentrations are listed in millimolar, unless otherwise noted. Dissecting solution: 50 N,N-Bis(2-hydroxyethyl)taurine, 30.83 potassium-propionate, 10 Na-azide, 20 EGTA, 6.29 MgCl~2~, 6.09 ATP, 1 dithiothreitol, 20 2,3-butanedione monoxime, 50 µM leupeptin, 275 µM Pefabloc (Acros Organics), and 1 µM E-64. Skinning solution: dissecting solution with 1% Triton-X-100 (wt/vol) and 50% glycerol (wt/vol). Storage solution: dissecting solution and 50% glycerol (wt/vol). Relaxing solution: pCa 8.0, 5 EGTA, 5 MgATP, 1 Mg^2+^, 0.3 P~i~, 35 phosphocreatine, and 300 U/ml creatine kinase, 200 ionic strength (pH 7.0). Activating solution: same as relaxing solution with pCa 4.8. Alkaline phosphatase (AP) solution: same as relaxing solution with 6 U/ml recombinant AP from *Escherichia coli*. Myosin light chain kinase (MLCK) solution: same as relaxing with pCa 6.0, 1.1 µM human skeletal MLCK, and 12 µM *Xenopus* calmodulin.

Skinned myocardial strips {#s06}
-------------------------

Left ventricular papillary muscles were dissected from each heart and pared down to thin strips (500--700 µm long and 150--200 µm wide at their minor and major axes, forming an ellipse). Strips were skinned overnight at 4°C and stored at −20°C for up to 1 wk. Aluminum T-clips were attached to the end of each strip, and the strips were mounted between a piezoelectric motor (P841.40; Physik Instrumente) and a strain gauge (AE801; Kronex), lowered into a 30-µl droplet of relaxing solution maintained at 17°C, and stretched to 1.9- or 2.2-µm SL measured by digital Fourier transform (IonOptix Corp.). We had previously investigated whether some cardiac effects of hypothyroidism may be partially related to changes in myofilament protein phosphorylation, specifically a decrease in Ca^2+^ sensitivity of contraction caused by increased troponin I phosphorylation. However, we found that AP treatment of skinned myocardial strips removed any of these effects ([@bib63]). Consequently, we applied a similar AP pretreatment to our strips to produce a homogeneous phosphorylation profile among all experiments, and we did not observe any significant differences between PTU strips (herein) and non-PTU strips ([@bib45]).

All strips were pretreated in AP solution at room temperature for 10 min and mounted on the experimental apparatus in relaxing solution (pCa 8.0). After AP pretreatment, one group of strips was calcium activated from pCa 8.0 to pCa 4.8; there was no detectable RLC phosphorylation in these AP-treated strips. Another group of strips underwent the AP pretreatment, after which the strips were incubated in MLCK solution for 30 min, and then these strips received the identical Ca^2+^-activation protocol as the AP-treated strips. The mean percentage of RLC phosphorylation was 67.8 ± 5.5% in MLCK-treated strips ([Fig. 2](#fig2){ref-type="fig"}; quantified with ImageJ \[National Institutes of Health\] as described by [@bib45]). At least two strips from each of the eight hearts underwent the mechanics protocol for each condition, with the total number of strips for each condition listed in [Table 1](#tbl1){ref-type="table"}.

![**In vitro RLC phosphorylation of skinned papillary muscle strips.** Western blot after 1-d isoelectric gel electrophoresis shows the typical ratios of nonphosphorylated RLC and phosphorylated RLC (RLC-P) in skinned papillary muscle strips that were used for mechanics measurements. AP-treated strips showed no detectible RLC-P, whereas MLCK-treated strips showed ∼68% RLC-P.](JGP_201812158_Fig2){#fig2}

###### Values from the four-parameter Hill fits to tension--pCa relationships at 1.9- and 2.2-µm SLs

  Parameter               1.9 µm         2.2 µm                                                            
  ----------------------- -------------- -------------- -------------------------------------------------- --------------------------------------------------
  *T*~min~ (kN ⋅ m^−2^)   0.39 ± 0.09    0.39 ± 0.07    3.08 ± 0.40[^a^](#ttbl1n2){ref-type="table-fn"}    2.73 ± 0.32[^a^](#ttbl1n2){ref-type="table-fn"}
  *T*~max~ (kN ⋅ m^−2^)   23.88 ± 0.90   23.36 ± 1.28   30.50 ± 2.09[^a^](#ttbl1n2){ref-type="table-fn"}   34.37 ± 2.05[^a^](#ttbl1n2){ref-type="table-fn"}
  pCa~50~                 5.48 ± 0.02    5.49 ± 0.03    5.51 ± 0.02                                        5.57 ± 0.03[^a^](#ttbl1n2){ref-type="table-fn"}
  *n*~H~                  7.3 ± 0.2      7.1 ± 0.3      6.5 ± 0.4[^a^](#ttbl1n2){ref-type="table-fn"}      6.4 ± 0.3
  *n* strips              20             18             16                                                 16

Data are means ± SEM. *T*~min~, *T*~max~, pCa~50~, and n~H~ represent fit parameters to a four-parameter Hill equation for the absolute tension versus pCa relationship:$T\left( {pCa} \right) = \left( {T_{\max}/\left\lbrack {1 + 10^{n_{H}{({pCa - pCa_{50}})}}} \right\rbrack} \right) + T_{\min}.$

P \< 0.05, effect of SL within the AP- or MLCK-treated group.

Dynamic mechanical analysis {#s07}
---------------------------

Stochastic length perturbations were applied for a period of 60 s, as previously described ([@bib57], [@bib59]), by using an amplitude distribution with an SD of 0.05% muscle lengths over the frequency range 0.125--100 Hz. Elastic and viscous moduli, *E*(ω) and *V*(ω), were measured as a function of angular frequency (ω) from the in-phase and out-of-phase portions of the tension response to the stochastic length perturbation. Viscoelastic myocardial stiffness is represented by the complex modulus *Y*(ω) = *E*(ω) + *iV*(ω), where *i* = √−1. Fitting [Eq. 1](#e1){ref-type="disp-formula"} to the entire frequency range of moduli values provided estimates of six model parameters (*A*, *k*, *B*, 2π*b*, *C*, and 2π*c*).$$Y\left( \omega \right) = A\left( {i\omega} \right)^{k} - B\left( \frac{i\omega}{2\pi b + i\omega} \right) + C\left( \frac{i\omega}{2\pi c + i\omega} \right).$$The A-term in [Eq. 1](#e1){ref-type="disp-formula"} reflects the viscoelastic mechanical response of passive, structural elements in the muscle and holds no enzymatic dependence. The parameter *A* represents the combined mechanical stress of the strip, and the parameter *k* describes the viscoelasticity of these passive elements, where *k* = 0 represents a purely elastic response and *k* = 1 is a purely viscous response ([@bib38]; [@bib42]). The B- and C-terms reflect enzymatic cross-bridge cycling behavior that produce frequency-dependent shifts in the viscoelastic mechanical response during Ca^2+^-activated contraction. These B- and C-processes characterize work-producing (cross-bridge recruitment) and work-absorbing (cross-bridge detachment) muscle responses, respectively ([@bib23]; [@bib5]; [@bib41]). The parameters *B* and *C* represent the mechanical stress from the cross-bridges (i.e., number of cross-bridges formed × their mean stiffness), and the rate parameters 2π*b* and 2π*c* reflect cross-bridge kinetics that are sensitive to biochemical perturbations affecting enzymatic activity. Molecular processes contributing to recruitment and force generation underlie the cross-bridge recruitment rate, 2π*b*. Similarly, processes contributing to cross-bridge detachment or force decay underlie the cross-bridge detachment rate, 2π*c*.

Statistical analysis {#s08}
--------------------

All values are shown as mean ± SEM. Constrained nonlinear least squares fitting of [Eq. 1](#e1){ref-type="disp-formula"} to complex moduli values was performed with sequential quadratic programming methods in Matlab (Mathworks). Statistical tests were performed with SPSS (IBM Statistics), using linear mixed models with pCa or frequency as a repeated measure for data shown in [Figs. 3](#fig3){ref-type="fig"}, [4](#fig4){ref-type="fig"}, and [5](#fig5){ref-type="fig"}, using main effects of MLCK treatment or SL, followed by a least significant difference post hoc comparison of the means. Linear mixed models were also applied to the parameter values for the four-parameter Hill fits to the tension--pCa relationships ([Table 1](#tbl1){ref-type="table"}) and fits to [Eq. 1](#e1){ref-type="disp-formula"} (see [Fig. 6](#fig6){ref-type="fig"}).

Results {#s09}
=======

Isometric tension--pCa relationships {#s10}
------------------------------------

Isometric tension developed in a sigmoidal manner as skinned rat papillary muscle strips were Ca^2+^-activated from pCa 8.0 to 4.8 ([Fig. 3](#fig3){ref-type="fig"}). These tension--pCa relationships were fitted to a four-parameter Hill equation ([Table 1](#tbl1){ref-type="table"}). As SL increased from 1.9 to 2.2 µm, Ca^2+^-activated tension increased and became more sensitive to \[Ca^2+^\] for both AP- and MLCK-treated strips (P \< 0.001 for main effects of pCa, SL, and the pCa × SL interaction). MLCK treatment also increased tension development and Ca^2+^ sensitivity of the tension--pCa relationship, but only at the longer (2.2-µm) SL (P = 0.017 for the pCa × MLCK interaction). Ca^2+^-activated tension increased more because of increased SL than increased RLC phosphorylation upon MLCK treatment. Increasing SL also led to robust increases in passive tension under relaxed conditions (pCa 8.0), without any significant effects of MLCK on passive tension ([Table 1](#tbl1){ref-type="table"}). These data show that the effect of RLC phosphorylation on Ca^2+^-activated force development in myocardial strips becomes more pronounced as SL increases.

![**RLC phosphorylation affected the tension--pCa relationship more at longer SLs. (A and B)** Developed tension--pCa relationships at 1.9-µm (A) and 2.2-µm (B) SLs for AP-treated and MLCK-treated skinned papillary muscle strips. Solid lines represent Hill fits to the tension--pCa data, with the dashed line representing the Hill fit of AP treated at 1.9-µm SL (replotted in B). \*, P \< 0.05; \#, P \< 0.1 between AP- and MLCK-treated conditions within each panel.](JGP_201812158_Fig3){#fig3}

Myocardial viscoelasticity under relaxed conditions {#s11}
---------------------------------------------------

Under relaxed conditions, myocardial viscoelasticity increased as SL increased from 1.9 to 2.2 µm, but there was no statistically significant effect of MLCK treatment at either SL ([Fig. 4](#fig4){ref-type="fig"}). Elastic moduli values were greater in 2.2- versus 1.9-µm SL strips for both AP- and MLCK-treated conditions at all frequencies \>0.5 Hz ([Fig. 4 A](#fig4){ref-type="fig"}; P \< 0.001 for main effects of frequency and SL). Viscous moduli values were also greater for 2.2- versus 1.9-µm SL ([Fig. 4 B](#fig4){ref-type="fig"}; P = 0.014 for main effect of frequency, P \< 0.001 for main effect of SL), but these viscous moduli differences were not as large as the elastic moduli differences. These data also suggest that the length-dependent increases in viscoelastic myocardial stiffness arise from passive elements of the sarcomere (i.e., titin and collagen; [@bib18]), being stretched or extended more at 2.2-µm SL than at 1.9-µm SL. Their study suggests that titin dominates the passive response toward the shorter end of the working range for cardiac sarcomeres (SL ∼1.9--2.2 µm), whereas collagen dominates at longer lengths (≥2.15 µm).

![**RLC phosphorylation did not influence myocardial viscoelasticity under relaxed conditions. (A and B)** Elastic (A) and viscous (B) moduli were plotted against frequency at 1.9- and 2.2-µm SLs for AP- and MLCK-treated papillary muscle strips under relaxed conditions (pCa 8).](JGP_201812158_Fig4){#fig4}

Myocardial viscoelasticity under Ca^2+^-activated conditions {#s12}
------------------------------------------------------------

Both SL and MLCK treatment influenced the magnitude and frequency dependence of myocardial viscoelasticity near half-maximal activation (pCa 5.5) and at maximal calcium activation (pCa 4.8), shown in [Fig. 5](#fig5){ref-type="fig"}. We will initially focus on the effects of pCa level and SL within AP- and MLCK-treated strips and then will describe the effect of RLC phosphorylation. Comparing moduli responses within a panel illustrates the effect of submaximal versus maximal Ca^2+^ activation. For both SLs, the elastic ([Fig. 5, A and B](#fig5){ref-type="fig"}) and viscous ([Fig. 5, C and D](#fig5){ref-type="fig"}) moduli values were greater at pCa 4.8 versus 5.5, as expected because of greater cross-bridge binding and tension development at pCa 4.8. As SL increased from 1.9 to 2.2 µm, the magnitude of the elastic and viscous moduli values increased for AP- and MLCK-treated strips at both pCa levels (P \< 0.001 for main effects of frequency, SL, and the frequency × SL interaction at both pCa 4.8 and 5.5). These data show robust increases in the elastic and viscous moduli values as Ca^2+^ activation and SL increased, whereas the effects of RLC phosphorylation caused by MLCK treatment were more subtle.

![**RLC phosphorylation influenced myocardial viscoelasticity under Ca^2+^-activated conditions at longer SLs. (A and B)** Elastic moduli were plotted against frequency at 1.9-µm (A) and 2.2-µm (B) SLs for AP- and MLCK-treated skinned papillary muscle strips under maximally activated conditions (pCa 4.8) and submaximally activated conditions near half-maximal tension (pCa 5.5). **(C and D)** The associated viscous moduli were plotted against frequency at 1.9-µm (C) and 2.2-µm (D) SLs. Lines represent fits to [Eq. 1](#e1){ref-type="disp-formula"} for the complex moduli versus frequency relationships. Because frequency varied at either pCa 4.8 or 5.5, moduli values differed between AP- and MLCK-treated conditions at 2.2 µm SL. \*, P \< 0.05; \#, P \< 0.1.](JGP_201812158_Fig5){#fig5}

MLCK treatment did not affect myocardial viscoelasticity at 1.9-µm SL at either pCa level ([Fig. 5, A and C](#fig5){ref-type="fig"}). Under maximal Ca^2+^-activated conditions (pCa 4.8) at 2.2-µm SL, MLCK treatment did not affect elastic moduli values and only modestly increased viscous moduli values between the frequencies of 6 and 8 Hz ([Fig. 5 D](#fig5){ref-type="fig"}; P = 0.05 for main effect of MLCK treatment, P \< 0.001 for the frequency × MLCK interaction). At submaximal activation (pCa 5.5) and 2.2-µm SL, MLCK treatment increased elastic moduli values \>55 Hz and viscous moduli between 5 and 14 Hz ([Fig. 5, B and D](#fig5){ref-type="fig"}, respectively; P \< 0.001 for main effect of MLCK treatment). Shifts in the magnitude and frequency characteristics of this viscoelastic system response under Ca^2+^-activated conditions reflect differences in cross-bridge cycling behavior. Typically, these kinetic parameters are reflected by the relative dips and peaks of the raw elastic and viscous modulus values at the lower to mid-frequency cycles, whereas the elastic modulus values continue to increase with frequency because of faster oscillations that sample a more "static" system where bridges appear to remain bound throughout a cycle period ([@bib41], [@bib42]; [@bib40]). Altogether, these moduli data show that the relative effects of RLC phosphorylation related to MLCK treatment were greatest at 2.2-µm SL and largely consistent between maximal and submaximal Ca^2+^ activation levels.

Moduli values were fitted to [Eq. 1](#e1){ref-type="disp-formula"} to extract model parameters related to myocardial viscoelasticity, cross-bridge binding, and cross-bridge kinetics under maximally activated (pCa 4.8) and submaximally activated (pCa 5.5) conditions as SL and RLC phosphorylation varied ([Fig. 6](#fig6){ref-type="fig"}). At both levels of Ca^2+^ activation, *A* values increased at longer SL in AP- and MLCK-treated strips ([Fig. 6 A](#fig6){ref-type="fig"}). For both Ca^2+^ activation levels, *k* values also decreased at longer SL in AP-treated strips ([Fig. 6 B](#fig6){ref-type="fig"}). In combination, these increases in *A* and decreases in *k* indicate a more elastic characteristic of the myocardium at longer SL, which primarily arises from nonenzymatic (passive) characteristics of the tissue.

![**RLC phosphorylation influenced myocardial viscoelasticity and cross-bridge behavior at pCa 4.8 and 5.5.** Parameter values from fits to [Eq. 1](#e1){ref-type="disp-formula"} are shown for AP-and MLCK-treated strips as SL and Ca^2+^ activation varied. **(A and B)** Myocardial viscoelastic stiffness increased and became increasingly elastic as SL increased at pCa 4.8 and 5.5, reflected by the length-dependent increase in *A* values (A) and decrease in *k* values (B). **(C and E)** Magnitude parameters for the B processes (C) and C processes (E) increased with RLC phosphorylation at 2.2-µm SL for both Ca^2+^ activation levels. **(D and F)** The rate of cross-bridge recruitment, 2π*b* (D), was similar among all conditions, but the rate of cross-bridge detachment, 2π*c* (F), slowed at 2.2-µm SL at maximal Ca^2+^ activation (pCa 4.8). \*, P \< 0.05; \#, P \< 0.1 for an MLCK effect at the same SL; ^†^, P \< 0.05 for an SL effect within a group of AP- or MLCK-treated strips. Means ± SEM of each dataset are shown as the dot ± error bar just to the left of each scatter plot, within a panel.](JGP_201812158_Fig6){#fig6}

For both Ca^2+^ activation levels, *B* and *C* values increased at longer SL for MLCK-treated strips ([Fig. 6, C and E](#fig6){ref-type="fig"}). This suggests greater cross-bridge binding with RLC phosphorylation at 2.2-µm SL, providing a molecular mechanism that underlies the phosphorylation-dependent increases in tension observed at longer SL ([Fig. 3 B](#fig3){ref-type="fig"}). SL and MLCK treatment did not show a statistically significant effect on cross-bridge recruitment rate ([Fig. 6 D](#fig6){ref-type="fig"}, 2π*b*), nor were there any consistent changes in recruitment rates between the two calcium activation levels in the entire set of measurements. However, the cross-bridge detachment rate (2π*c*) slowed as SL increased under maximally activated conditions, with and without RLC phosphorylation ([Fig. 6 F](#fig6){ref-type="fig"}), which could prolong the myosin duty ratio and contribute to greater cross-bridge binding upon RLC phosphorylation at 2.2-µm SL. There was a subtle increase in cross-bridge detachment rate as calcium activation decreased from pCa 4.8 to 5.5, but this change was only statistically significant for the rates at 2.2-µm SL (∼30% faster ± RLC phosphorylation; P \< 0.05). Again, these data suggest that the molecular effects of RLC phosphorylation that augment cross-bridge binding and force production become greater as SL increases.

Discussion {#s13}
==========

Effects of RLC phosphorylation of β-myosin heavy chain isoform are SL dependent {#s14}
-------------------------------------------------------------------------------

In this study, we performed biophysical muscle mechanics measurements to assess the influences of RLC phosphorylation and SL on the tension--pCa relationship and cross-bridge cycling kinetics in skinned rat papillary muscle strips that predominantly expressed the slower, cardiac β-myosin heavy chain isoform. RLC phosphorylation increased maximal isometric tension, calcium sensitivity of the tension--pCa relationship, and viscoelastic myocardial stiffness at submaximal calcium activation, but only at long SL (2.2 µm). These results suggest that RLC phosphorylation augments the number of bound cross-bridges and/or stiffness of force-generating cross-bridges, but this effect is more prominent at long SLs in myocardium containing β-myosin heavy chain. Cross-bridge detachment rate slowed as SL increased under maximally activated conditions. This slowed detachment rate could result in prolonged cross-bridge binding at longer SLs, which may contribute to greater contractility during systole in response to greater end-diastolic filling volumes. Collectively, these findings suggest that in myocardium predominantly expressing the β-myosin heavy chain isoform, the effects of RLC phosphorylation on tension development are codependent on SL. This study further indicates that RLC phosphorylation plays an important role in regulating myosin contributions to length-dependent activation of contraction.

The decrease in cross-bridge detachment rate at longer SLs (2π*c*, [Fig. 6](#fig6){ref-type="fig"}), with and without RLC phosphorylation, is associated with a longer duty ratio leading to increased viscoelastic myocardial stiffness as SL increased ([Fig. 5](#fig5){ref-type="fig"}). The relative shifts in viscoelastic myocardial stiffness that depend on RLC phosphorylation were smaller than the associated SL dependence. Moreover, the RLC-dependent increases in active viscoelasticity did not accompany frequency-dependent shifts in 2π*b* or 2π*c*, even though the viscoelastic changes in RLC phosphorylation drove significant changes in *B* and *C* parameter values that represent cross-bridge binding. Overall, SL-dependent increases in cross-bridge binding and tension show the dominant effect. Any RLC phosphorylation--dependent increases in cross-bridge stiffness are not readily observed at shorter SLs and may be diminished by lower tension values and fewer cross-bridges binding at 1.9-µm SL. Therefore, the differences in active viscoelasticity related to RLC phosphorylation become more apparent at the longer SL because the effect of RLC phosphorylation on cross-bridge stiffness may be subtle, and increased cross-bridge recruitment dominates.

Relationship to our prior studies using myocardial strips expressing α-myosin heavy chain {#s15}
-----------------------------------------------------------------------------------------

Our previous study ([@bib45]) showed that RLC phosphorylation increased Ca^2+^-sensitivity of contraction and maximal tension development at both 1.9- and 2.2-µm SL in MLCK-treated myocardial strips that primarily contained the faster cardiac α-myosin heavy chain isoform. In the current study, we observed a more robust length-dependent effect of tension development in β-myosin heavy chain isoform than in our prior study, with RLC phosphorylation augmenting length-dependent activation of contraction only at the longer SL ([Fig. 3](#fig3){ref-type="fig"}), which suggests that RLC phosphorylation increases cross-bridge binding for β-myosin heavy chain at long SLs, but not at short SLs. RLC phosphorylation of α-myosin heavy chain increased cross-bridge binding to augment Ca^2+^ sensitivity of the tension--pCa relationship at both SLs. It is noteworthy that tension values were similar in phosphorylated and dephosphorylated strips at submaximal Ca^2+^ concentrations in both β- and α-myosin heavy chain isoforms ([Fig. 3](#fig3){ref-type="fig"} and [@bib45]). Thus, it is unlikely that there were significant differences in the population of cross-bridges bound for either myosin heavy chain isoform between these two studies. However, in combination, these studies suggest that β-myosin heavy chain is more sensitive to changes in SL, and the effects of RLC phosphorylation become amplified as SL increases for the β-myosin heavy chain isoform. Perhaps, with α-myosin heavy chain being less sensitive to changes in SL, the relative effects of RLC phosphorylation (vs. SL) influence α-myosin heavy chain cross-bridge activity more greatly over a broader range of SL values.

In addition to these effects of RLC phosphorylation on tension development, we observed that increasing SL slowed cross-bridge detachment rate at maximum Ca^2+^ activation with both RLC phosphorylation and dephosphorylation in β-myosin heavy chain isoform ([Fig. 6 F](#fig6){ref-type="fig"}). This slowed cross-bridge detachment rate would increase the amount of time cross-bridges bind with actin, potentially contributing to the increased maximum tension observed at longer SLs. This finding differs from that of our prior study, in which RLC phosphorylation slowed cross-bridge detachment at both 1.9- and 2.2-µm SL ([@bib45]). Thus, cross-bridge cycling kinetics were more length dependent in myocardial preparations containing β-myosin heavy chain versus the α-myosin heavy chain isoform (consistent with prior observations in mouse myocardium; [@bib58]).

We also noted no significant differences in cross-bridge recruitment rates for the β-myosin heavy chain isoform with increases in SL ([Fig. 6 D](#fig6){ref-type="fig"}), in contrast with our prior study of the α-myosin heavy chain isoform, in which cross-bridge recruitment rate decreased at 2.2-µm SL. Notably, RLC phosphorylation increased the number of bound cross-bridges at maximal and submaximal Ca^2+^ concentrations for the β-myosin heavy chain isoform ([Fig. 6, C and E](#fig6){ref-type="fig"}), which is consistent with our previous findings in α-myosin heavy chain. This consistency suggests that the number of cross-bridges bound is a fundamental mechanism contributing to greater tension development at longer SLs, regardless of the cardiac myosin heavy chain isoform. For the β-myosin heavy chain isoform, we observed increased viscoelastic stiffness at long SL at both submaximal and maximal Ca^2+^ concentration ([Fig. 6 A](#fig6){ref-type="fig"}), which was comparable with our findings for the α-myosin heavy chain isoform, but more pronounced in this current study. Together, these data suggest that increased viscoelastic stiffness stems from, or is associated with, greater cross-bridge contributions to length-dependent tension development as SL increases.

Viscous and elastic moduli increased with SL in relaxed strips, but there was no significant change in viscous and elastic moduli with RLC phosphorylation in relaxed strips at either SL. RLC phosphorylation--dependent differences in active moduli occurred only in activated strips. This supports the tension data suggesting that effects of RLC phosphorylation on myosin mechanics are exerted through changes in active contractile processes rather than passive tension. Activated differences in viscous and elastic moduli with RLC phosphorylation were seen only at long SL ([Fig. 5](#fig5){ref-type="fig"}), which is consistent with RLC phosphorylation effects on tension ([Fig. 3](#fig3){ref-type="fig"}).

Differential myosin heavy chain expression may have functional consequences {#s16}
---------------------------------------------------------------------------

β-myosin heavy chain expression correlates negatively with heart rate across various mammal species, with animals of resting heart rates \<300 beats per minute predominantly expressing the β-myosin heavy chain isoform in the ventricular myocardium ([@bib22]). Thus, relative changes in the speed of molecular processes scale with required speeds to accommodate heart rate, and slower heart rates may allow for more filling time and greater SL dependence to augment power output and larger blood flow volumes in larger animals ([@bib22]). Overall, studies have found decreased cross-bridge cycling kinetics in β-myosin heavy chain isoform versus α-myosin heavy chain isoforms ([@bib27]; [@bib48]). This difference seems to be related to myosin ATPase activity in both isoforms, with α-myosin heavy chain expressing faster myosin ATPase activity and β-myosin heavy chain demonstrating slower ATPase activity ([@bib22]). However, these effects are highly length-dependent in β-myosin heavy chain, and the relative length-dependent sensitivity of cross-bridge cycling kinetics is greater for β- versus α-myosin heavy chain in skinned rat myocardial strips ([@bib58]). In β-myosin heavy chain myocytes, previous studies noted an increase in cross-bridge cycling kinetics at short SL versus long SL that was more closely related to lattice spacing versus tension ([@bib26]). This effect of lattice spacing on cross-bridge cycling was less pronounced in α-myosin heavy chain strips, which were more affected by tension. Moreover, those authors showed greater SL dependence of loaded shortening and peak power output of skinned cardiomyocytes containing β- versus α-myosin heavy chain. In combination with our findings, these data may indicate that the different responsiveness to SL changes between these myosin heavy chain isoforms stems from different sensitivities to myofilament stress or load versus myofilament geometry or lattice spacing. Thus, increased length dependence in β-myosin heavy chain strips may confer functional benefits in human cardiac ventricles (and in hearts of larger mammals), where the operating range of SLs and transmural stress--strain heterogeneities may be greater than those observed for rats or mice ([@bib30]). Thus, a greater sensitivity to SL and lattice spacing may result in a steeper Frank--Starling relationship in cardiac tissues predominantly expressing β-myosin heavy chain.

RLC phosphorylation plays a critical role in modulating contractility for both cardiac myosin heavy chain isoforms {#s17}
------------------------------------------------------------------------------------------------------------------

We noted that RLC phosphorylation increased tension for both myosin heavy chain isoforms, particularly at long SL ([Fig. 3](#fig3){ref-type="fig"}; [@bib45]). This effect may be attributed to smaller thick-to-thin filament spacing as SL increases, sterically promoting cross-bridge binding ([@bib34]; [@bib18]; [@bib25]; [@bib51]). RLC phosphorylation may reposition myosin heads close to the thin filament, further decreasing thick-to-thin filament distance ([@bib8]). Simultaneously, these changes in lattice spacing may provide a physical explanation for decreased cross-bridge detachment rates at longer SLs for both myosin heavy chain isoforms ([Fig. 6 F](#fig6){ref-type="fig"}; [@bib45]).

Altogether, these data suggest functional consequences of RLC phosphorylation, regardless of myosin heavy chain isoform expression. Previous studies suggested that RLC phosphorylation may increase myosin stiffness in skeletal muscle ([@bib19]). Computational models of cardiac contractility have suggested that RLC phosphorylation enhances twitch force and ventricular torsion throughout a heartbeat ([@bib50]) because of increased cross-bridge stiffness (or greater "observed power-stroke size") as well as faster cross-bridge attachment rates to augment contractility. Combined cross-bridge and twitch mechanics models implementing these multiple mechanisms of RLC phosphorylation were required to recapitulate the measured RLC phosphorylation responses---neither mechanism was sufficient alone ([@bib50]). Consistent with these computational predictions, other groups have used single-molecule techniques to measure increases in myosin step size upon RLC phosphorylation for both skeletal and cardiac myosins ([@bib64]), which could contribute to the greater force production that we observed. Our studies measured viscoelastic myocardial stiffness at submaximal and maximal Ca^2+^ concentrations in both myosin heavy chain isoforms ([Fig. 5](#fig5){ref-type="fig"} and [@bib45]). In our study, RLC phosphorylation produced subtle, but statistically significant, increases in myocardial viscoelastic stiffness for myocardial strips expressing β-myosin heavy chain, which could arise from greater numbers of cross-bridges bound ([Fig. 6 C](#fig6){ref-type="fig"}) or increases in myosin step-size and stiffness, particularly at 2.2-µm SL ([@bib50]; [@bib64]). In contrast, RLC phosphorylation produced slight decreases in viscoelastic myocardial stiffness at both short and long SLs for myocardial strips expressing the α-myosin heavy chain isoform ([@bib45]), suggesting that RLC phosphorylation leads to minimal change or could even decrease α-myosin heavy chain cross-bridge stiffness.

Steric repositioning of the myosin head nearer to thin filaments upon RLC phosphorylation ([@bib29]), along with any potential effects of RLC phosphorylation on cross-bridge stiffness, could combine to alter the strain-dependent or load-dependent kinetics of force-bearing cross-bridges. Increasing SL may independently reduce lattice spacing to diminish cross-bridge strain as well. However, RLC phosphorylation may amplify this effect at long SL to increase myosin step size and slow cross-bridge detachment rate ([Fig. 6 F](#fig6){ref-type="fig"}; [@bib64]). This mechanism would be expected to augment force production in both myosin heavy chain isoforms, agreeing with our findings of increased Ca^2+^-sensitivity of the tension--pCa relationship observed herein and previously ([@bib45]).

RLC phosphorylation and heart disease {#s18}
-------------------------------------

At the organ level, the Frank--Starling law of the heart links increased contractility with increased ventricular filling to dynamically accommodate contractile demand on a beat-to-beat basis. Recently, a handful of studies have started to generate a detailed understanding of the intrinsic role that cross-bridge kinetics plays in length-dependent muscle contraction ([@bib2]; [@bib35]; [@bib36]; [@bib59]; [@bib3]). RLC phosphorylation has been implicated in properly timing contraction to enhance ventricular torsion ([@bib10]; [@bib50]), and reductions in RLC phosphorylation accompany cardiac stress and the progression of heart failure ([@bib49]; [@bib61]; [@bib11]; [@bib50]; [@bib65]; [@bib6]). Reduced RLC phosphorylation has also been linked with RLC mutations that cause hypertrophic cardiomyopathy in humans and mice ([@bib56]; [@bib1]; [@bib20]; [@bib24]). Altogether, it is clear that RLC phosphorylation is an important modulator of cardiac function over multiple biological scales, which has motivated a handful of preclinical studies trying to target RLC phosphorylation as a therapeutic mechanism to modulate ventricular function and help prevent the pathological development of cardiomyopathies ([@bib50]; [@bib65]; [@bib6]; [@bib70]).

We showed that the effects of RLC phosphorylation on β-myosin heavy chain contraction are enhanced at longer SLs. As stated previously, SL increases as the ventricle fills, and RLC phosphorylation may help to increase power output from the contracting myocardium to maintain the Frank--Starling law. It is likely that RLC phosphorylation plays an important role in this response, but clearly there are myriad other myofilament proteins that help modulate cross-bridge activity and myocardial contractility throughout a heartbeat. Nonetheless, these data support the idea that a basal level of RLC phosphorylation would benefit normal cardiac function ([@bib7]), and dysregulation or decreases in RLC phosphorylation might then lead to signaling for hypertrophic compensation, ultimately manifesting as hypertrophic cardiomyopathy. Better understanding this mechanism may be a key to understanding the pathogenesis of severe forms of hypertrophic cardiomyopathy with sudden cardiac death.

Potential effects of PTU-induced hypothyroidism {#s19}
-----------------------------------------------

Passive tension is predominantly caused by titin at shorter SLs and collagen at longer SLs ([@bib18]). PTU-induced hypothyroidism has been shown to induce myofibril and myofilament disorganization, disruption, and rupture; increase interstitial substance; and reduce fiber mass ([@bib32]; [@bib33]). To explore the effects this might have on passive tension, we performed a *t* test comparing our PTU-treated measurements to those in a previous study from our laboratory ([@bib45]). Between the two studies, passive tension decreased in PTU-treated strips at 1.9-µm SL; from 0.72 to 0.39 kN ⋅ m^−2^ for AP-treated strips (P = 0.0001) and from 0.54 to 0.39 kN ⋅ m^−2^ for MLCK-treated strips (P = 0.0001). When comparing similar passive tension measurements at 2.2-µm SL between the two studies, we found no significant effects of PTU, irrespective of AP or MLCK treatment. We suspect that any myofibril disruption from PTU would contribute to less passive tension at the 1.9-µm SL, because titin is an integral part of the sarcomere. Primary hypothyroidism has been shown to increase interstitial collagen deposition in rat myocardium ([@bib12]), which we would expect to increase passive tension at longer SLs in PTU-treated strips that is related to increased collagen deposition, but this was not the case. Thus, there may be some subtle myofibrillar or ultrastructural differences caused by PTU treatment that have a small effect on length-dependent passive tension development.

Apart from any potential structural differences, decreased passive tension values could follow from changes in titin isoform expression elicited by PTU treatment. Hypothyroidism may lead to alternative splicing or signaling that switches titin isoform expression from the adult N2B titin isoform to the more compliant fetal N2BA titin isoform ([@bib68]; [@bib28]). Further study of this isoform in bovine myocardium showed that greater expression of N2BA titin blunted length-dependent tension development and Ca^2+^ sensitivity of contraction ([@bib16]). Thus, we might have expected our observed effects of SL to be blunted by a similar switch in titin isoform expression, rather than enhanced effects of SL and RLC phosphorylation at long SLs that we measured herein. One important note is that these length-dependent changes from titin isoform switching required preincubation in protein kinase A ([@bib69]; [@bib16]).

SR calcium ATPase (SERCA2), β-adrenergic receptors, sodium/potassium ATPases, and several potassium channels (K~v~1.5, K~v~4.2, and K~v~4.3) have been shown to be affected by hypothyroidism ([@bib21]). Although these proteins are necessary for cardiac function, we controlled Ca^2+^ activation and electrolyte concentrations in our solutions. Therefore, although hypothyroidism may induce cardiac dysfunction, any differences we would expect to see in our preparations may solely underlie the differences in passive tension discussed at the beginning of this section and should not affect our results regarding active tension development and cross-bridge kinetics. Furthermore, any structural changes would have been present in all of our fibers, but our results showed changes in contractility only at longer SL associated with MLCK incubation. Altogether, these findings and potential limitations imply that the changes in active tension development and Ca^2+^ sensitivity that we observed stem from length-dependent effects of MLCK treatment and increased RLC phosphorylation, rather than aberrant artifacts of PTU treatment.

In the present study, we developed an understanding of the interaction of β-myosin heavy chain and RLC, two proteins implicated in the development of heart failure and particularly hypertrophic cardiomyopathy. Heavy accumulation of extracellular matrix and increased myocardial stiffness are hallmarks of hypertrophied and failing hearts ([@bib4]; [@bib67]; [@bib62]; [@bib66]). Although we have outlined potential hypothyroid-induced changes in the myocardium, we believe these changes do not influence our overall conclusions, but acknowledge that they may also contribute to fibrotic cardiac remodeling associated with hypertrophic cardiomyopathy and the progression of heart failure (none of which were readily observable in the PTU-treated rat hearts used in this study).
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